RASSF1A及其甲基化与乳腺癌的关系

doi:10.11904/j.issn.1002-3070.2015.04.019

摘要/Abstract

摘要： 乳腺癌是女性最常见的恶性肿瘤之一。早期诊断在乳腺癌的治疗中起着重要的作用。近年来随着表观遗传学的发展,为肿瘤的早期检测提供了新的方向。在表观遗传学中DNA甲基化与乳腺癌的关系的研究最为广泛,RASSF1A(ras相关区域家族基因1A)甲基化发生在乳腺癌的早期,与肿瘤的TNM分期、侵袭性以及预后有关。同时RASSF1A的甲基化是可逆的,因此RASSF1A甲基化的研究可为乳腺癌的早期诊断提供生物靶点,也为乳腺癌的治疗提供了一个潜在的研究方向。

关键词: 乳腺癌, DNA甲基化, RASSF1A, 雌激素受体-α

Abstract: Breast cancer is one of the most common malignant tumors in women.Early diagnosis plays a very important role in the treatment of breast cancer.Recently,with the development of epigenetics,it gives us a new orientation for early detection for cancers.The most understood mechanism of epigenetics is DNA methylation.Ras associated domain family 1A gene(RASSFlA)promoter methylation occurres in tumor′s early stage,and have a statistically concern with tumor′s TNM stage,invasiveness and outcomes.Moreover,DNA methylation can be reversed,so RASSF1A can be a promising candidate for early breast cancer detection biomarker,and can be a potential orientation for breast cancer treatment.

Key words: Breast cancer, DNA methylation, RASSF1A, Estrogen receptor-α

中图分类号:

R737.9

吕付龙,王泽涛,王劲松. RASSF1A及其甲基化与乳腺癌的关系[J]. 实用肿瘤学杂志, 2015, 29(4): 372-375.

LV Fulong,WANG Zetao,WANG Jinsong. RASSF1A and RASSF1A methylation′s relationship with breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 372-375.

参考文献

1 Waddington CH.The epigenotype.1942[J].Int J Epidemiol,2012,41(1):10-13.
2 Rountree MR,Bachman KE,Herman JG,et al.DNA methylation,chromatin inheritance and cancer[J].Oncogene,2001,20(24):3156-3165.
3 van Hoesel AQ,Sato Y,Elashoff DA,et al.Assessment of DNA methylation status in early stages of breast cancer development[J].Br J Cancer,2013,108(10):2033-2038.
4 Dammann R,Li C,Yoon JH,et al.Epigenetic inactivation of aRAS association domain family protein from the lung tumour suppressor locus 3p21.3[J].Nat Genet,2000,25(3):315-319.
5 Hagrass HA,Pasha HF,Shaheen MA,et al.Methylation status and protein expression of RASSF1A in breastcancer patients[J].Mol Biol Rep,2014,41(1):57-65.
6 Kloten V,Becker B,Winner K,et al.Promoter hypermethylation of the tumor-suppressor genes ITIH5,DKK3,and RASSF1A as novel biomarkers for blood-based breast cancer screening[J].Breast Cancer Research,2013,15(1):R4.
7 Liu L,Tommasi S,Lee DH,et al.Control of microtubule stability by the RASSFIA tumor suppressor[J].Oncogene,2003,22(50):8125-8136.
8 Rong R,Jin W,Zhang J,et al.Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest[J].Oncogene,2004,23(50):8216-8230.
9 Shivakumar L,Minna J,Sakamaki T,et al.The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation[J].Mol Cell Biol,2002,22(12):4309-4318.
10 Whang YM,Kim YH,Kim JS,et al.RASSFlA suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression[J].Cancer Res,2005,65(9):3682-3690.
11 Burbee DG,Forgacs E,Zochbauer-Muller S,et al.Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotypesuppression[J].J Natl Cancer Inst,2001,93(9):691-699.
12 Alvarez C,Tapia T,Cornejo V,et al.Silencing of tumor suppressor genes RASSF1A,SLIT2,and WIF1 by promoter hypermethylation in hereditary[J].Molecular Carcinogenesis,2013,52(6):475-487.
13 Bediaga NG,Acha-Sagredo A,Guerra I.DNA methylation epigenotypes in breast cancer molecular subtypes[J].Breast Cancer Res,2010,12(5):R77.
14 Thaler S,Schmidt M,Schad A,et al.RASSF1A inhibits estrogen receptor alpha expression andestrogen-independent signalling:implications for breast cancer development[J].Oncogene,2012,31(47):4912-4922.
15 Strunnikova M,Schagdarsurengin U,Kehlen A,et al.Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter[J].Mol Cell Biol,2005,25(10):3923-3933.
16 Klajic J,Fleischer T,Dejeux E,et al.Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors[J].BMC Cancer,2013,13:456.
17 Xu J,Shetty PB,Feng W,et al.Methylation of HIN-1,RASSF1A,RIL and CDH13 in breast cancer is associated with clinical characteristics,but only RASSF1A methylation is associated with outcome[J].BMC Cancer,2012,12:243.
18 Gil EY,Jo UH,Jeong H,et al.Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer[J].International Journal of Oncology,2012,41(2):611-620.
19 Müller HM,Widschwendter A,Fiegl H,et al.DNA methylationin serum of breast cancer patients:an independent prognostic marker[J].Cancer Res,2003,63(15):7641-7645.
20 Dou S,Yao YD,Yang XZ,et al.Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy[J].J Control Release,2012,161(3):875-883.
21 Du L,Xie Z,Wu LC,et al.Reactivation of RASSF1A in breast cancer cells by curcumin[J].Nutr Cancer,2012,64(8):1228-1235.
22 Montenegro MF,Sáez-Ayala M,Piero-Madrona A,et al.Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation[J].PLoS One,2012,7(12):e52231.
23 Lirk P,Berger R,Hollmann MW,et al.Lidocaine time-and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro[J].British Journal of Anaesthesia,2012,109(2):200-207.
24 赵丽娜,张丽杰,任云会.抑癌基因RASSF1A与乳腺癌发生发展关系的研究[J].实用肿瘤学杂志,2011,25(3):233-237.
25 廖粤军,魏付桥,谢文彪.EGCG对乳癌细胞RAFFS1A基因表达及甲基化的影响[J].中医临床研究,2014,6(21):133-135.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[12]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[13]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[14]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[15]	李红阳, 孙亮, 姜醒, 苑光军, 刘艳. 蝙蝠葛碱在人乳腺癌MCF-7细胞对5氟尿嘧啶敏感性的研究[J]. 实用肿瘤学杂志, 2017, 31(5): 385-389.